The primary objective of the IMPROVE-AD trial is to
determine whether an upfront invasive strategy of TEVAR
plus medical therapy reduces the occurrence of a composite
endpoint of all-cause death or major aortic complications
compared to an upfront conservative strategy of medical
therapy with surveillance for deterioration in patients with
uncomplicated type B aortic dissection followed for up to six
years with a primary assessment at four years.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
